Biostate AI

Name: Biostate AI
Brand: Biostate AI

AI Native

Biostate AI is a combined wet-lab sequencing and machine learning platform that generates transcriptomic and genomic data at reduced per-sample cost and trains predictive models for disease risk and drug/therapy response.

Est 2023|Valuation $65M|Raised $16.7M|6 Ref Customers

LinkedIn 13K|Web traffic 3K|FTEs 37

01Competitive Landscape

Narrative analysis

Where Biostate may be appropriate: If the vendor’s cost profile and sample-type compatibility match an organization’s needs, the vendor’s model could permit larger cohort sizes for discovery studies. Integration of sequencing and dataset creation may reduce handoffs in some workflows.
Where alternatives may be preferable:
- Illumina/DRAGEN: for enterprises that prioritize standardized, widely adopted pipelines and vendor maturity.
- Tempus: for customers that require clinical-grade testing, an established clinical data infrastructure, and healthcare integrations.
Adoption signals: Biostate is early-stage relative to incumbents; public materials emphasize funding and partnerships more than broad independent customer evidence.

- Where Biostate may be appropriate: If the vendor’s cost profile and sample-type compatibility match an organization’s needs, the vendor’s model could permit larger cohort sizes for discovery studies. Integration of sequencing and dataset creation may reduce handoffs in some workflows. - Where alternatives may be preferable: - Illumina/DRAGEN: for enterprises that prioritize standardized, widely adopted pipelines and vendor maturity. - Tempus: for customers that require clinical-grade testing, an established clinical data infrastructure, and healthcare integrations. - Adoption signals: Biostate is early-stage relative to incumbents; public materials emphasize funding and partnerships more than broad independent customer evidence.

	Biostate AI	Illumina (DRAGEN / Connected Analytics ecosystem)	Tempus (clinical/precision medicine data + AI)
Starting Price	Not publicly posted (quote-based likely)	Some DRAGEN/Connected Analytics costs are documented; other elements are contract-based	Pricing is typically contract-based and varies by service
Best For	Organizations seeking lower-cost RNAseq at scale combined with a model-training partnership	Organizations standardizing genomics workflows and secondary analysis within Illumina's ecosystem	Organizations seeking multimodal clinical and molecular data with established clinical integrations
Key Strength	Vendor-stated integration of wet-lab cost reduction and dataset generation for model training	Mature ecosystem, established pipelines, extensive documentation	Large clinical data focus and healthcare integration experience
Key Weakness	Limited independent reviews and limited publicly documented security posture; pricing opacity	Potential vendor lock-in and scale-dependent costs	Complex offerings with contract-based pricing and variable focus on low-cost RNAseq

Biostate AI

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map